ACADIA Pharmaceuticals (ACAD) Stock Price, Quote, News & History | Benzinga

ACADIA Pharmaceuticals Inc (ACAD) Stock Price, Quote, News & History

ACADNASDAQ

Trade with Public

Trade with Public

$21.48

-0.87-3.89%

At close: May 6, 5:00 PM EST

$21.75

0.271.26%

After Hours: 5:10 PM EST

Earnings: Q1 2026 earnings were released today after the market close

Conference Call: Today's conference call started over 5 hours ago

Click to view the webcast

OverviewNews Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Key Statistics

Open

$22.54

Close

$21.48

Volume / Avg.

3.41M / 1.82M

Day Range

$21.36 - $23.07

52 Wk Range

14.45 - 28.35

Market Cap

$3.72B

P/E Ratio

9.72

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

10.17%

Days to Cover

7.39

Recent ACADIA Pharmaceuticals Inc News

EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug

EU drug advisers issued a negative vote on Acadia's Rett syndrome treatment trofinetide. The company plans to seek a re-examination after the opinion is formally adopted.

Vandana Singh

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.

Vandana Singh

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory

Acadia wins Nuplazid patent case, extending protection to 2038, as JP Morgan boosts price target ahead of key appeal on the ‘740 COM patent.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

109.84M

Investing Cash Flow (TTM)

-302.56M

Financing Cash Flow (TTM)

49.88M

Free Cash Flow (TTM)

105.15M

Capital Expenditure (TTM)

-4.69M

Net Change in Cash (TTM)

-142.85M

Analyst Trends and Forecast

1

Nov 25

1

1

Dec 25

2

Jan

6

Feb

2

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$3.06B

PE Ratio (TTM)

9.72

PE Ratio (FWD)

51.28

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.54

PB Ratio (TTM)

3.12

Earnings Yield % (TTM)

10.29%

Earnings Yield % (FWD)

1.95%

EV / EBITDA (TTM)

26.24

Price / EBITDA (TTM)

32.58

Price / Free Cash Flow (TTM)

36.12

Book Value / Share

$7.17

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$177.70M

Debt to Equity

0.04

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$22.54

Close

$21.48

Volume / Avg.

3.41M / 1.82M

Day Range

$21.36 - $23.07

52 Wk Range

14.45 - 28.35

Market Cap

$3.72B

P/E Ratio

9.72

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

10.17%

Days to Cover

7.39

About

Sector

Health Care

Industry

Biotechnology

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare dise...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy ACADIA Pharmaceuticals (ACAD) stock?

A

You can purchase shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) through any online brokerage.

View our list of the best stock brokerages

Q

Who are ACADIA Pharmaceuticals (ACAD) competitors?

A

Other companies in ACADIA Pharmaceuticals’s space includes: Legend Biotech Corp (NASDAQ:LEGN), Twist Bioscience Corp (NASDAQ:TWST), Arcutis Biotherapeutics Inc (NASDAQ:ARQT), Tango Therapeutics Inc (NASDAQ:TNGX) and Xenon Pharmaceuticals Inc (NASDAQ:XENE).

Q

What is the forecast, or price target, for ACADIA Pharmaceuticals (ACAD) stock?

A

ACADIA Pharmaceuticals has a consensus price target of $30.18.

Q

What is the current price for ACADIA Pharmaceuticals (ACAD)?

A

The stock price for ACADIA Pharmaceuticals (NASDAQ: ACAD) is $21.75 last updated May 6, 2026 at 5:10 PM EDT.

Q

Does ACADIA Pharmaceuticals (ACAD) pay a dividend?

A

There are no upcoming dividends for ACADIA Pharmaceuticals.

Q

When is ACADIA Pharmaceuticals (NASDAQ:ACAD) reporting earnings?

A

ACADIA Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is ACADIA Pharmaceuticals (ACAD) going to split?

A

There is no upcoming split for ACADIA Pharmaceuticals.

Q

What sector and industry does ACADIA Pharmaceuticals (ACAD) operate in?

A

ACADIA Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Legend Biotech Corp

Twist Bioscience Corp

Arcutis Biotherapeutics Inc

Tango Therapeutics Inc

Xenon Pharmaceuticals Inc

PTC Therapeutics Inc

Viking Therapeutics Inc

Kiniksa Pharmaceuticals International PLC